水凝胶间隔物对前列腺近距离放疗后直肠与泌尿毒性的影响
本研究回顾性分析224例接受低剂量率前列腺近距离放疗(联合或不联合外照射)并放置直肠水凝胶间隔物(HSP)的患者,与139例未放置HSP的类似患者比较。结果显示HSP显著降低直肠剂量,并降低总体及≥2级直肠毒性发生率,3年累积总体直肠毒性显著降低(15% vs 33%,P<0.001),而未发现尿道剂量学变量或HSP与晚期泌尿毒性相关。
要点
- HSP显著降低直肠剂量学参数,减少晚期直肠毒性。
- HSP组3年累积总体直肠毒性为15%,非HSP组为33%(P<0.001)。
- HSP与晚期泌尿毒性无关,尿道剂量学变量亦无关联。
核心结论
- 直肠水凝胶间隔物放置安全,显著降低直肠剂量并减少剂量递增近距离放疗患者的总体晚期直肠毒性。
研究设计与样本
- 回顾性比较研究,HSP组224例,非HSP组139例,均为2016年1月至2019年12月接受低剂量率近距离放疗(单用或联合外照射)的前列腺癌患者。
主要发现
- HSP组总体直肠毒性发生率为12%,≥2级为1.8%;非HSP组分别为31%和5.8%。
- HSP组3年累积总体直肠毒性为15%,非HSP组为33%(P<0.001)。
- 单变量分析显示HSP与总体直肠毒性降低相关(风险比0.45,95%CI 0.28-0.73;P=0.001)。
- 尿道剂量学变量及HSP有无均与晚期泌尿毒性无关。
临床怎么用
- 在前列腺近距离放疗(尤其剂量递增方案)中可考虑放置直肠水凝胶间隔物以降低直肠毒性。
局限性
- 回顾性研究设计,样本来自单中心,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the influence of rectal hydrogel spacer placement (HSP) on late rectal toxicity outcomes in prostate cancer patients treated with low-dose-rate (LDR) brachytherapy, with or without supplemental external beam radiotherapy (EBRT). PATIENTS AND METHODS: A total of 224 patients underwent LDR brachytherapy with HSP, as monotherapy or combined with EBRT, between January 2016 and December 2019. Dosimetric variables reflecting the extent of rectal sparing and late rectal toxicity outcomes were evaluated. This spacer cohort was retrospectively compared to a similar patient group (n = 139) in whom HSP was not used. RESULTS: Hydrogel spacer placement was associated with significantly reduced rectal doses for all dosimetric variables; the median percentage rectal dose to 1 cc of rectum and rectal dose to 2 cc of rectum of the spacer cohort were all significantly lower compared to the non-spacer cohort. The incidence rates of overall (any grade) and grade ≥2 rectal toxicity were lower in patients with HSP compared to patients who did not undergo HSP: 12% and 1.8% vs 31% and 5.8%, respectively. The 3-year cumulative incidence of overall rectal toxicity was significantly lower with HSP than without (15% vs 33%; P < 0.001), corresponding to an overall rectal toxicity reduction on univariable analysis (hazard ratio 0.45, 95% confidence interval 0.28-0.73; P = 0.001). In this patient cohort treated with prostate brachytherapy, none of the urethral dosimetric variables or the presence or absence of HSP was associated with late urinary toxicity. CONCLUSION: Hydrogel rectal spacer placement is a safe procedure, associated with significantly reduced rectal dose. HSP translates to a decrease in overall late rectal toxicity in patients receiving dose-escalated brachytherapy-based procedures.
引用
- Teyateeti A, Grossman C, Kollmeier MA, et al. Influence of hydrogel spacer placement with prostate brachytherapy on rectal and urinary toxicity. BJU Int. 2021. PMID: 34388295. doi:10.1111/bju.15572
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。